Here's Won't Touch Teva: Why I Pass on the Generic Giant
Teva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
This intro covers zero-fee index funds available in 2024, helping you compare costs and identify cost-efficient options for long-term investing.
15,531 articlesTeva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
A solid move by a seasoned fund—Alpine Capital Research increases its Arrow Electronics position. Learn what this cou...
Global markets jitters rose as Iran’s leadership tensions intensified, threatening energy supply risk and currency vo...
As market conditions shift in early 2026, those earning $400K face tougher retirement math. This report outlines the ...
Microsoft's stock has faced a meaningful pullback this year. This article unpacks the factors behind the drop, evalua...
A top institutional trader doubled down on PTCT, adding thousands of shares in a high-conviction move. This analysis ...
A major manager disclosed a sizable stake reduction in BXP, prompting questions about the outlook for Class A office ...
Markets swing as geopolitical tensions flare between the U.S. and Iran. This analysis traces the past CIA plan and ex...
Claude AI projects a multi-year rally for XRP, SOL, and ADA, with end-2026 targets that would mark fresh highs amid i...
A midrange, budget-friendly Apple device could broaden the company’s market and boost services revenue. This guide an...
Prediction markets pricing pennies on a Bitcoin 150K scenario sound far-fetched—until you unpack how odds, liquidity,...
A premium fitness brand attracts a substantial fund investment while its stock lags. This piece breaks down what it m...